首页> 外文期刊>Diabetes >Nitric oxide-sensitive soluble guanylyl cyclase activity is preserved in internal mammary artery of type 2 diabetic patients.
【24h】

Nitric oxide-sensitive soluble guanylyl cyclase activity is preserved in internal mammary artery of type 2 diabetic patients.

机译:一氧化氮敏感的可溶性鸟苷酰环化酶活性在2型糖尿病患者的乳内动脉中得以保留。

获取原文
获取原文并翻译 | 示例
       

摘要

Vascular reactivity to nitric oxide (NO) is mediated by NO-sensitive soluble guanylyl cyclase (sGC). Since a diminished activity of vascular sGC has been reported in an animal model of type 2 diabetes, the sGC activity was assayed in vitro in internal mammary artery specimens obtained during bypass surgery from patients with and without type 2 diabetes. The sensitivity of sGC to NO, which is dependent on Fe(2+)-containing heme, was measured in vitro using stimulation with diethylamine NONOate (DEA/NO). In addition, the novel cyclic guanosine monophosphate-elevating compound HMR-1766 was used to test the stimulation of the oxidized heme-Fe(3+)-containing form of sGC. Basal activity of sGC and its sensitivity to stimulation by DEA/NO and HMR-1766 were not different between control and type 2 diabetic patients: maximum stimulation by DEA/NO amounted to 475 +/- 67 and 418 +/- 59 pmol. mg(-1). min(-1) in control and type 2 diabetic patients, respectively. The maximum effects of HMR-1766 were 95 +/- 18 (control subjects) and 83 +/- 11 pmol. mg(-1). min(-1) (type 2 diabetic patients). Hypertension, hyperlipidemia, drug treatment with statins, ACE inhibitors, or nitrates had no effect on sGC activity. In conclusion, the present findings do not support the hypothesis that desensitization of sGC contributes to the pathogenesis of diabetic vascular dysfunction in humans.
机译:一氧化氮(NO)的血管反应性是由NO敏感的可溶性鸟苷酸环化酶(sGC)介导的。由于据报道在2型糖尿病动物模型中血管sGC活性减弱,因此在体外手术中从患有和不患有2型糖尿病患者的乳腺内动脉样本中体外分析了sGC活性。 sGC对NO的敏感性,这取决于含Fe(2+)的血红素,在体外使用二乙胺NONOate(DEA / NO)的刺激进行了测量。此外,新型的环状鸟苷单磷酸酯化合物HMR-1766被用于测试sGC的氧化血红素-Fe(3+)形式的刺激。对照组和2型糖尿病患者的sGC基础活性及其对DEA / NO和HMR-1766刺激的敏感性没有差异:DEA / NO的最大刺激量为475 +/- 67和418 +/- 59 pmol。毫克(-1)。 min(-1)分别在对照组和2型糖尿病患者中。 HMR-1766的最大作用是95 +/- 18(对照组)和83 +/- 11 pmol。毫克(-1)。 min(-1)(2型糖尿病患者)。高血压,高血脂,他汀类药物,ACEI抑制剂或硝酸盐药物治疗对sGC活性无影响。总之,本发现不支持sGC脱敏导致人类糖尿病性血管功能障碍的发病机理的假说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号